|Bid||17.33 x 800|
|Ask||19.25 x 800|
|Day's Range||18.00 - 18.43|
|52 Week Range||12.89 - 21.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.79|
Tesaro’s (TSRO) Phase 3 PRIMA trial of Zejula to evaluate it for the treatment of women with newly diagnosed ovarian cancer, irrespective of BRCA mutation status, has been completely enrolled. Its Phase 2 trial of Zejula in combination with an anti-PD-1 antibody in first-line non-small cell lung cancer is ongoing. The company expects to present data in the first half of 2019. In its immuno-oncology pipeline, Tesaro plans to submit a BLA (Biologic License Application) for TSR-042 in 2019.
Tesaro (TSRO) is a commercial-stage biopharmaceutical company primarily focused on developing treatments for solid tumors by using small molecules and immune-oncology antibodies both as monotherapies and in combinations. Tesaro’s key product, Zejula, has been approved in the United States as well as the European Union as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Tesaro commercialized Zejula in the United States in April 2017 and in Europe in December 2017.
Bausch Health Companies’ (BHC) wholly-owned subsidiary Salix Pharmaceuticals reported revenue of $441 million in the second quarter compared to $387 million in the second quarter of 2017, which reflected ~14% YoY (year-over-year) growth.
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.
NEW YORK, Aug. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Omnicom ...
Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.
Ironwood (IRWD) delivered earnings and revenue surprises of -47.37% and -9.63%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of 32 cents per share. Losses, adjusted for amortization costs and non-recurring costs, came to 28 cents per share. The results fell short ...
– Second quarter revenue increased 25% year-over-year to $81 million, driven primarily by LINZESS® U.S. net sales of $192 million and commercial margin of 60% –
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Ironwood Pharmaceuticals, Inc. Class A (NASDAQ: IRWD ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 8:30 ...
Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding IRWD totaled $454 million.
Ironwood Pharmaceuticals, Inc. (IRWD) today announced it will host its second quarter 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Monday, August 6, 2018. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 5795089. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on HZNP sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today announced the initiation of a Phase IIIb clinical trial evaluating the efficacy and safety of linaclotide 290 mcg on multiple abdominal symptoms in addition to pain, including bloating and discomfort, in adult patients with irritable bowel syndrome with constipation (IBS-C). Linaclotide is a guanylate cyclase-C (GC-C) agonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with IBS-C or chronic idiopathic constipation (CIC).
NEW YORK, NY / ACCESSWIRE / June 25, 2018 / U.S. markets were mixed Friday, with the Dow snapping an eight day losing streak as energy shares rallied. However, major indexes experienced weekly losses on ...
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today presented additional data from an exploratory Phase IIa study of praliciguat (IW-1973) in patients with type 2 diabetes and hypertension during an oral session at the American Diabetes Association’s (ADA) 78th Scientific Sessions in Orlando, Fla. Praliciguat is an oral, once-daily soluble guanylate cyclase (sGC) stimulator that is currently being studied in Phase II clinical trials in patients with diabetic nephropathy and in patients with heart failure with preserved ejection fraction (HFpEF). Building on previously announced top-line data from the Phase IIa randomized, placebo-controlled, 14-day study, which showed that treatment with praliciguat led to reductions in blood pressure, fasting plasma glucose, cholesterol levels and triglycerides in patients on a stable regimen of medicines to manage their disease, the newly reported findings also suggested that praliciguat improved insulin sensitivity.
Ironwood (IRWD) initiates two phase III studies on its gastrointestinal candidate, IW-3718, to evaluate it in persistent gastroesophageal reflux disease.
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today announced the initiation of two Phase III clinical trials evaluating the safety and efficacy of IW-3718 in patients with persistent gastroesophageal reflux disease (GERD). Persistent GERD affects an estimated 10 million Americans who continue to suffer from heartburn and regurgitation despite receiving treatment with proton pump inhibitors (PPIs), the current standard of care. “We are excited to advance development of IW-3718 by initiating the Phase III trials,” said Christopher Wright, M.D., Ph.D., senior vice president, global development and chief development officer at Ironwood.
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotechnology company, today announced that the company will present clinical and preclinical data for the company’s soluble guanylate cyclase (sGC) stimulator praliciguat (IW-1973) during the American Diabetes Association’s (ADA) 78th Scientific Sessions in Orlando, Fla., June 22 through June 26, 2018. Praliciguat is currently being studied in Phase II clinical trials in patients with diabetic nephropathy and in patients with heart failure with preserved ejection fraction (HFpEF). Data from a Phase IIa 14-day study of praliciguat in patients with diabetes and hypertension will be featured as an oral presentation during the Emerging Targets for Diabetes Treatment session, presented by John P. Hanrahan, M.D., M.P.H., of Ironwood.
LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on IRWD sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com observes the recent performance of Horizon Pharma PLC (NASDAQ: HZNP), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Lipocine Inc. (NASDAQ: LPCN), and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN).
CNBC's Dominic Chu reports on Sarissa Capital Management's Alex Denner presenting his best investment ideas at Delivering Alpha.